Clinical Trials

Latanoprost has been extensively evaluated across numerous clinical trials spanning Phase 1 through Phase 4, primarily targeting ophthalmic conditions such as open-angle glaucoma, ocular hypertension, angle-closure glaucoma, and diabetic retinopathy, alongside exploratory dermatological uses like alopecia areata. Supported by both academic centers and pharmaceutical sponsors, these studies encompass completed, active, recruiting, and terminated statuses. Investigations evaluate conventional regimens as well as novel formulations, including sustained-release ocular implants and long-term intraocular pressure monitoring.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07425535 RECRUITING
Glaucoma
Johns Hopkins University
 2026-06-24 EARLY_PHASE1
NCT07325240 RECRUITING
Open Angle Glaucoma; Ocular Hypertension
Mayo Clinic
 2025-11-21 PHASE4
NCT07465913 RECRUITING
Glaucoma
Eye Centers of Southeast Texas
 2026-05-14 PHASE4
NCT04401982 RECRUITING
Ocular Hypertension; Suspect Glaucoma
University of Maryland, Baltimore
 2026-07-02 PHASE4
NCT07048886 NOT_YET_RECRUITING
Primary Open Angle Glaucoma
Center for Sight Las Vegas
 2025-07-15 PHASE4
NCT07209410 RECRUITING
Glaucoma
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
 2025-11-01 PHASE4
NCT06964191 ACTIVE_NOT_RECRUITING
Glaucoma, Open-Angle; Ocular Hypertension
PolyActiva Pty Ltd
 2025-05-31 PHASE2
NCT07310719 RECRUITING
Primary Open Angle Glaucoma or Ocular Hypertension
Lagos State Health Service Commission
 2025-10-15
NCT06666855 ACTIVE_NOT_RECRUITING
Open Angle Glaucoma; Ocular Hypertension
Santen Pharmaceutical Co., Ltd.
 2024-11-28 PHASE3
NCT07354516 COMPLETED
OAG - Open-Angle Glaucoma; OHT - Ocular Hypertension
Qlaris Bio, Inc.
 2026-03-18 PHASE2; PHASE3
NCT07082816 COMPLETED
Ocular Hypertension; Open Angle Glaucoma
Alcon Research
 2025-09-02 PHASE3
NCT06883123 RECRUITING
Open Angle Glaucoma
Prairie Eye Center
 2025-05-14 PHASE4
NCT06960629 COMPLETED
Pseudophakic Bullous Keratopathy; Glaucoma
University Hospital Dubrava
 2025-01-01 PHASE2; PHASE3
NCT06441643 COMPLETED
Open Angle Glaucoma; Ocular Hypertension
Alcon Research
 2024-09-04 PHASE2
NCT07016113 NOT_YET_RECRUITING
Vitiligo - Macular Depigmentation
Universitas Padjadjaran
 2025-07-01 PHASE2
NCT04500574 TERMINATED
Glaucoma; Ocular Hypertension
Massachusetts Eye and Ear Infirmary
 2024-04-03 PHASE1
NCT06449352 COMPLETED
Normal Tension Glaucoma
Westlake Eye Specialists
 2024-06-13 PHASE4
NCT04412096 COMPLETED
Glaucoma; OHT - Ocular Hypertension
Ohio State University
 2020-11-23 PHASE4
NCT04060758 COMPLETED
Open Angle Glaucoma
PolyActiva Pty Ltd
 2020-03-11 PHASE1
NCT04630808 COMPLETED
Open Angle Glaucoma; Ocular Hypertension
Nicox Ophthalmics, Inc.
 2020-11-09 PHASE3
NCT04761705 SUSPENDED
Ocular Hypertension; Open Angle Glaucoma
JeniVision, Inc.
 2021-03-10 PHASE1; PHASE2
NCT06407973 TERMINATED
Primary Open Angle Glaucoma
Sight Sciences, Inc.
 2024-08-21 PHASE4
NCT06249152 COMPLETED
Open-angle Glaucoma (OAG); Ocular Hypertension (OHT); Glaucoma
Qlaris Bio, Inc.
 2024-04-21 PHASE2
NCT05583474 COMPLETED
Open Angle Glaucoma or Ocular Hypertension
Otsuka Beijing Research Institute
 2022-09-27 PHASE3
NCT02390284 TERMINATED
Glaucoma
University of Miami
 2015-09 PHASE3
NCT07757867 COMPLETED
Microneedling-Assisted Delivery; Cetirizine; Latanoprost; Alopecia Areata
Tanta University
 2022-10-01
NCT05935527 COMPLETED
Lower Eyelid Steatoblepharon
Peregrine Ophthalmic
 2023-04-28 PHASE1
NCT06730516 COMPLETED
Glaucoma
Zagazig University
 2024-06-24 EARLY_PHASE1
NCT06629129 COMPLETED
Treatment Outcome
Zagazig University
 2024-06-24 PHASE1
NCT06369077 TERMINATED
Glaucoma, Open-Angle; Glaucoma; Drugs
CT Glaucoma Associates
 2024-04-22 PHASE4
NCT06239324 UNKNOWN
Alopecia Areata
Egymedicalpedia
 2024-02-01 PHASE1; PHASE2
NCT04811326 UNKNOWN
Non-segmental Vitiligo
Shaimaa Fawzy Abdel-rady Abdel-latif
 2021-01-13 PHASE4
NCT04702789 TERMINATED
Glaucoma, Open-Angle; Ocular Hypertension
Laboratorios Sophia S.A de C.V.
 2021-10-19 PHASE4
NCT02585375 UNKNOWN
Glaucoma; Ocular Hypertension
Medical University of Vienna
 2015-09-17 PHASE4
NCT05606796 UNKNOWN
Effect of Drug
Uzoma Chinyei Joan
 2022-12 PHASE4
NCT05790941 UNKNOWN
Hypotrichosis
Aneira Pharma, Inc.
 2023-03-11 EARLY_PHASE1
NCT05333419 COMPLETED
Open Angle Glaucoma; Ocular Hypertension
PolyActiva Pty Ltd
 2022-03-04 PHASE1
NCT05495061 COMPLETED
Primary Open Angle Glaucoma, Ocular Hypertension
Santen Pharmaceutical Co., Ltd.
 2022-08-09 PHASE3
NCT05283395 COMPLETED
Glaucoma
Aerie Pharmaceuticals
 2022-03-28 PHASE4
NCT04448223 UNKNOWN
Primary Open Angle Glaucoma; Ocular Hypertension
Chong Kun Dang Pharmaceutical
 2020-06-11 PHASE2
NCT05513924 COMPLETED
Vitiligo
South Valley University
 2022-03-15 PHASE2; PHASE3
NCT04445519 COMPLETED
Open Angle Glaucoma; Ocular Hypertension
Nicox Ophthalmics, Inc.
 2020-06-01 PHASE3
NCT05165290 UNKNOWN
Elevated Intraocular Pressure
TearClear Corp
 2021-11-29 PHASE3
NCT03648229 WITHDRAWN
Open-angle Glaucoma
West Virginia University
 2019-09-01 PHASE4
NCT05299593 UNKNOWN
Glaucoma, Open-Angle; Ocular Hypertension
Fondazione G.B. Bietti, IRCCS
 2020-06-04 PHASE4
NCT05333419 Completed
Open Angle Glaucoma|Ocular Hypertension
PolyActiva Pty Ltd
 2022-03-04 Phase 1
NCT03762369 UNKNOWN
Primary Open-angle Glaucoma; Ocular Hypertension
Chong Kun Dang Pharmaceutical
 2018-12-07 PHASE3
NCT03697811 COMPLETED
Primary Open-angle Glaucoma and Ocular Hypertension
Santen Inc.
 2018-09-27 PHASE3
NCT04891588 UNKNOWN
Primary Open-angle Glaucoma; Ocular Hypertension
Klinički Bolnički Centar Zagreb
 2021-03-08
NCT03284853 COMPLETED
Open Angle Glaucoma; Ocular Hypertension
Aerie Pharmaceuticals
 2017-09-05 PHASE3
NCT04405245 COMPLETED
Ocular Hypertension; Primary Open Angle Glaucoma
EyePoint Pharmaceuticals, Inc.
 2020-06-06 PHASE2
NCT03949244 COMPLETED
Glaucoma, Open-Angle
Icahn School of Medicine at Mount Sinai
 2019-08-15 PHASE4
NCT04098861 UNKNOWN
Primary Open Angle Glaucoma
Universiti Kebangsaan Malaysia Medical Centre
 2019-01-02 PHASE4
NCT04743622 COMPLETED
Glaucoma; Ocular Hypertension
CHA University
 2019-04-30 PHASE4
NCT04178863 UNKNOWN
Glaucoma; Drugs
Intuor Technologies, Inc.
 2018-07-01 PHASE4
NCT04205201 COMPLETED
To See the Safety and Efficacy of the Topical Latanoprost Compared With Topical Brimonidine in the Treatment of the Primary Open Angle Glaucoma Patients
Chittagong Medical College
 2018-06-25 PHASE2
NCT03611348 UNKNOWN
Vitiligo
Sohag University
 2018-09-01 PHASE2; PHASE3
NCT02656979 UNKNOWN
Glaucoma
Umeå University
 2013-12
NCT03657797 COMPLETED
Glaucoma, Open-Angle; Hypertension, Ocular
Nicox Ophthalmics, Inc.
 2018-08-01 PHASE2
NCT03318146 UNKNOWN
Glaucoma; Ocular Hypertension; IOP
Shaare Zedek Medical Center
 2018-06-01
NCT04737928 COMPLETED
Glaucoma, Primary Open Angle
Santen Pharmaceutical (Taiwan) Co., LTD
 2018-04-02
NCT02981446 COMPLETED
Open Angle Glaucoma or Ocular Hypertension
Santen Pharmaceutical Co., Ltd.
 2017-01 PHASE3
NCT03612817 COMPLETED
Glaucoma, Open-Angle
Aristotle University Of Thessaloniki
 2017-01 PHASE4
NCT03480906 COMPLETED
Intraocular Pressure
Eyenovia Inc.
 2018-03-12
NCT02167035 COMPLETED
Glaucoma; Ocular Hypertension
Cornerstone Health Care, PA
 2014-08 PHASE4
NCT03216902 COMPLETED
Open-angle Glaucoma, Ocular Hypertension
Santen Inc.
 2017-07-25 PHASE2
NCT03274323 WITHDRAWN
Glaucoma, Open-Angle
Johns Hopkins University
 2018-01-12
NCT03419975 COMPLETED
Primary Open-angle Glaucoma; Ocular Hypertension
Taejoon Pharmaceutical Co., Ltd.
 2016-04-26 PHASE3
NCT03293992 COMPLETED
Glaucoma, Open-angle; Ocular Hypertension
Hoffmann-La Roche
 2017-10-10 PHASE1
NCT03331770 COMPLETED
Primary Open-angle Glaucoma
Laboratorios Poen
 2017-01-06 PHASE4
NCT03067415 UNKNOWN
Glaucoma, Primary Open Angle; Ocular Hypertension
Chong Kun Dang Pharmaceutical
 2017-03-30 PHASE2
NCT02829996 COMPLETED
Primary Open-Angle Glaucoma (POAG); Ocular Hypertension (OHT)
Inotek Pharmaceuticals Corporation
 2016-08-19 PHASE2
NCT02558400 COMPLETED
Open-angle Glaucoma; Ocular Hypertension
Aerie Pharmaceuticals
 2015-09-18 PHASE3
NCT02129673 COMPLETED
Open Angle Glaucoma; Ocular Hypertension
ViSci Ltd.
 2014-05 PHASE1; PHASE2
NCT02822742 COMPLETED
Primary Open Angle Glaucoma or Ocular Hypertension
Santen Pharmaceutical Co., Ltd.
 2016-07-02 PHASE3
NCT02792803 UNKNOWN
POAG; Primary Open Angle Glaucoma; Ocular Hypertension
Dr. David Yan
 2015-09 PHASE4
NCT02674854 COMPLETED
Open-angle Glaucoma; Ocular Hypertension
Aerie Pharmaceuticals
 2016-02 PHASE3
NCT02623738 COMPLETED
Primary Open Angle Glaucoma; Ocular Hypertension
Santen Pharmaceutical Co., Ltd.
 2015-12-06 PHASE2; PHASE3
NCT02014142 COMPLETED
Ocular Hypertension; Open-Angle Glaucoma
Mati Therapeutics Inc.
 2013-12 PHASE2
NCT01527682 COMPLETED
Childhood Glaucoma
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
 2009-07 PHASE2
NCT01677507 COMPLETED
Glaucoma; Healthy
University of Michigan
 2012-08 PHASE4
NCT02622334 COMPLETED
Glaucoma
Hoffmann-La Roche
 2015-12-29 PHASE1
NCT07412587 COMPLETED
Androgenetic Alopecia (AGA); Telogen Effluvium; Female Pattern Hair Loss, Androgenic Alopecia
Medical University of Warsaw
 2015-07-08
NCT01973114 UNKNOWN
Menière's Disease
Synphora AB
 2013-10 PHASE2
NCT02466399 COMPLETED
Glaucoma
Peregrine Ophthalmic
 2015-07 PHASE2
NCT02531152 COMPLETED
Open Angle Glaucoma -Ocular Hypertension
Sanofi
 2015-09 PHASE1
NCT02622334 Completed
Glaucoma
Hoffmann-La Roche
 2015-12-29 Phase 1
NCT02802137 COMPLETED
Glaucoma; Ocular Surface Disease
Aristotle University Of Thessaloniki
 2015-03 PHASE4
NCT02278614 COMPLETED
Open Angle Glaucoma; Ocular Hypertension
Laboratoires Thea
 2014-12 PHASE3
NCT02105272 COMPLETED
Glaucoma; Ocular Hypertension
Otsuka Pharmaceutical Co., Ltd.
 2014-04 PHASE3
NCT02350023 COMPLETED
Alopecia Areata
Post Graduate Institute of Medical Education and Research, Chandigarh
 2014-09 PHASE4
NCT01975714 COMPLETED
Glaucoma; Ocular Hypertension
Association for Innovation and Biomedical Research on Light and Image
 2013-10 PHASE4
NCT03966560 COMPLETED
Glaucoma, Open-Angle
Afyon Kocatepe University Hospital
 2014-01 PHASE4
NCT02059278 COMPLETED
Primary Open Angle Glaucoma; Ocular Hypertension
Nephron Pharmaceuticals Corporation
 2014-01 PHASE3
NCT02179008 COMPLETED
Open-angle Glaucoma; Ocular Hypertension
Santen Inc.
 2014-06 PHASE2
NCT02047630 TERMINATED
Primary Open Angle Glaucoma; Ocular Hypertension
CHU de Quebec-Universite Laval
 2014-01 PHASE4
NCT01225653 COMPLETED
Diabetic Retinopathy
University of Aarhus
 2010-11 PHASE4
NCT02083289 COMPLETED
Ocular Hypertension; Open Angle-glaucoma
Ono Pharmaceutical Co., Ltd.
 2014-05 PHASE2
NCT02522039 COMPLETED
Drug Effect (Glaucoma Drugs)
Glostrup University Hospital, Copenhagen
 2014-05
NCT01175902 COMPLETED
Normal Tension Glaucoma
The Catholic University of Korea
 2011-03
NCT01917383 COMPLETED
Primary Open-Angle Glaucoma (POAG); Ocular Hypertension (OHT)
Inotek Pharmaceuticals Corporation
 2013-08 PHASE2
NCT00941525 COMPLETED
Open Angle Glaucoma; Ocular Hypertension
Aristotle University Of Thessaloniki
 2009-09 PHASE4
NCT02057575 COMPLETED
Open Angle Glaucoma; Ocular Hypertension
Aerie Pharmaceuticals
 2014-01 PHASE2
NCT01180062 TERMINATED
Primary Open Angle Glaucoma (POAG); Ocular Hypertension (OHT)
Daniel Moore
 2011-01 PHASE1
NCT02108288 COMPLETED
Glaucoma; Ocular Hypertension
Otsuka Pharmaceutical Co., Ltd.
 2014-04 PHASE1
NCT01896180 COMPLETED
Primary Open Angle Glaucoma; Ocular Hypertension; Elevated Intraocular Pressure
Alleanza Pharmaceuticals, Inc.
 2013-07 PHASE2
NCT01315574 TERMINATED
Glaucoma
Massachusetts Eye and Ear Infirmary
 2011-02 PHASE4
NCT01201551 COMPLETED
Primary Vascular Dysregulation
University Hospital, Basel, Switzerland
 2011-06
NCT01639807 UNKNOWN
Glaucoma
Aurolab
 2011-10
NCT01868126 COMPLETED
Open-angle Glaucoma or Ocular Hypertension
Santen Inc.
 2013-05 PHASE2
NCT01987323 COMPLETED
Ocular Hypertension
Singapore Eye Research Institute
 2013-01 PHASE1; PHASE2
NCT01433900 UNKNOWN
Glaucoma
Paolo Fogagnolo
 2012-05 PHASE3
NCT01731002 COMPLETED
Ocular Hypertension; Open Angle Glaucoma
Aerie Pharmaceuticals
 2012-11 PHASE2
NCT01510145 COMPLETED
Open-angle Glaucoma; Ocular Hypertension
Alcon Research
 2012-02 PHASE4
NCT01721707 WITHDRAWN
Open Angle Glaucoma; Ocular Hypertension
Adapt Produtos Oftalmológicos Ltda.
 2012-12 PHASE3
NCT01493427 COMPLETED
Open-Angle Glaucoma; Ocular Hypertension
Alcon Research
 2011-12 PHASE4
NCT01779284 COMPLETED
Glaucoma
Aristotle University Of Thessaloniki
 2012-01 PHASE4
NCT01525173 COMPLETED
Glaucoma; Ocular Hypertension
Allergan
 2012-01 PHASE4
NCT01410188 COMPLETED
Primary Open-angle Glaucoma; Ocular Hypertension
Kubota Vision Inc.
 2011-09 PHASE1; PHASE2
NCT00913029 COMPLETED
Eye Diseases; Glaucoma, Open-Angle; Glaucoma
Glaukos Corporation
 2009-05 PHASE4
NCT01481077 COMPLETED
Glaucoma; Ocular Hypertension (OH)
Mati Therapeutics Inc.
 2011-11 PHASE2
NCT01481051 COMPLETED
Glaucoma; Ocular Hypertension (OH)
Mati Therapeutics Inc.
 2011-11 PHASE2
NCT01978015 COMPLETED
Uveitis, Anterior; Cystoid Macular Edema
University of Campinas, Brazil
 2011-10 PHASE4
NCT01369771 COMPLETED
Ocular Hypertension; Open-Angle Glaucoma
FinnMedi Oy
 2010-08 PHASE4
NCT01580254 UNKNOWN
Intraocular Pressure (IOP); Tear Break-Up Time
University of Catanzaro
 2011-06 PHASE4
NCT01430923 UNKNOWN
Glaucoma, Open-Angle; Ocular Hypertension
Aurolab
 2011-09
NCT01162603 COMPLETED
Primary Open Angle Glaucoma; Ocular Hypertension
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
 2011-03 PHASE4
NCT01243567 COMPLETED
Glaucoma, Open-Angle
Allergan
 2010-06-01 PHASE4
NCT01151904 TERMINATED
Glaucoma, Angle-Closure
Allergan
 2009-11 PHASE4
NCT01361841 UNKNOWN
Ocular Hypertension; Primary Glaucoma
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
 2009-01
NCT01223378 COMPLETED
Intraocular Pressure
Bausch & Lomb Incorporated
 2010-12-13 PHASE2
NCT01302249 COMPLETED
Glaucoma; Ocular Hypertension
Aerie Pharmaceuticals
 2011-02 PHASE2
NCT00815373 WITHDRAWN
Open-Angle Glaucoma; Ocular Hypertension
Meir Medical Center
 2008-12
NCT00872651 COMPLETED
Open-angle Glaucoma; Ocular Hypertension
Alcon Research
 2010-01 PHASE3
NCT01426464 UNKNOWN
Glaucoma
Nanduri, Padma, M.D., FACS
 2011-09 PHASE2
NCT01318252 COMPLETED
Open-angle Glaucoma (OAG); Ocular Hypertension (OHT)
Alcon Research
 2011-06 PHASE2
NCT01253902 COMPLETED
Glaucoma, Open-Angle; Ocular Hypertension
Allergan
 2010-12 PHASE4
NCT01229982 COMPLETED
Ocular Hypertension; Open Angle Glaucoma
Mati Therapeutics Inc.
 2010-10 PHASE2
NCT01254370 COMPLETED
Glaucoma; Ocular Hypertension; Ocular Surface Disease
Santen SAS
 2010-11 PHASE2
NCT00892762 COMPLETED
Open Angle Glaucoma; Ocular Hypertension
Alcon Research
 2009-06 PHASE3
NCT00705757 COMPLETED
Glaucoma; Application Site Pigmentation Changes
Summa Health System
 2008-03 PHASE4
NCT01448837 COMPLETED
Glaucoma
Aristotle University Of Thessaloniki
 2010-04 PHASE4
NCT00619034 COMPLETED
Diabetic Retinopathy
University of Aarhus
 2007-09
NCT01087671 COMPLETED
Ocular Hypertension; Open-Angle Glaucoma
Santen Oy
 2010-04 PHASE3
NCT01084902 UNKNOWN
Ocular Hypertension
Peking University First Hospital
 2010-02
NCT01060579 COMPLETED
Glaucoma
Aerie Pharmaceuticals
 2010-02 PHASE2
NCT00706927 COMPLETED
Retina; Ocular Physiology
Medical University of Vienna
 2006-01
NCT00972426 COMPLETED
Glaucoma
Taiwan Otsuka Pharm. Co., Ltd
 2009-10 PHASE4
NCT00934089 COMPLETED
Glaucoma, Open-Angle; Ocular Hypertension
Pfizer
 2010-01 PHASE2
NCT00967811 COMPLETED
Glaucoma; Ocular Hypertension
Mati Therapeutics Inc.
 2009-08 PHASE2
NCT00868894 COMPLETED
Open-Angle Glaucoma; Ocular Hypertension
Santen Inc.
 2009-03 PHASE1; PHASE2
NCT01037036 COMPLETED
Ocular Hypertension; Open-Angle Glaucoma
Mati Therapeutics Inc.
 2009-12 PHASE2
NCT00811564 COMPLETED
Glaucoma; Ocular Hypertension
Allergan
 2008-12 PHASE4
NCT00735449 COMPLETED
Glaucoma; Ocular Hypertension
Allergan
 2008-07 PHASE4
NCT00845299 COMPLETED
Glaucoma; Ocular Hypertension
Mati Therapeutics Inc.
 2009-01 PHASE2
NCT00820300 COMPLETED
Glaucoma; Ocular Hypertension
Mati Therapeutics Inc.
 2009-01 PHASE2
NCT00572936 COMPLETED
Glaucoma
University of Nebraska
 2006-03-13 PHASE2
NCT00821002 COMPLETED
Open-Angle Glaucoma; Ocular Hypertension
Mati Therapeutics Inc.
 2009-01 PHASE2
NCT00716859 COMPLETED
Glaucoma
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
 2008-07 PHASE3
NCT00887029 COMPLETED
Open-Angle Glaucoma; Ocular Hypertension
Ophthalmic Consultants Centres, Canada
 2009-01 PHASE4
NCT00761709 COMPLETED
Open-Angle Glaucoma; Ocular Hypertension
Alcon Research
 2009-07 PHASE2
NCT00712400 COMPLETED
Ocular Physiology; Intraocular Pressure; Regional Blood Flow
Medical University of Vienna
 2005-06
NCT00941525 Completed
Open Angle Glaucoma|Ocular Hypertension
Aristotle University Of Thessaloniki
 2009-09 Phase 4
NCT00761319 COMPLETED
Open-angle Glaucoma; Ocular Hypertension
Alcon Research
 2008-10 PHASE3
NCT00708422 COMPLETED
Glaucoma; Ocular Hypertension
Alcon Research
 2008-07 PHASE4
NCT00759941 COMPLETED
Glaucoma
Alcon Research
 2007-10 PHASE4
NCT00855517 WITHDRAWN
Glaucoma; Ocular Hypertension
Mati Therapeutics Inc.
 2009-03 PHASE2
NCT00572455 COMPLETED
Primary Open-Angle Glaucoma; Ocular Hypertension
Pfizer
 2007-12-11 PHASE2
NCT00690794 COMPLETED
Open-angle Glaucoma; Ocular Hypertension
Alcon Research
 2008-07 PHASE3
NCT00798759 COMPLETED
Open-angle Glaucoma; Ocular Hypertension
Alcon Research
 2008-12 PHASE4
NCT00846989 COMPLETED
Glaucoma; Ocular Hypertension
Novartis Pharmaceuticals
 2009-01 PHASE1; PHASE2
NCT00224289 COMPLETED
Glaucoma
Yale University
 2005-03 PHASE4
NCT00638742 COMPLETED
Glaucoma; Ocular Hypertension
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
 2008-05 PHASE1
NCT00757835 COMPLETED
Glaucoma
Aristotle University Of Thessaloniki
 2008-05 PHASE4
NCT00650702 COMPLETED
Glaucoma; Ocular Hypertension
Mati Therapeutics Inc.
 2008-03 PHASE2
NCT00698945 COMPLETED
Ocular Hypertension; Open-Angle Glaucoma
Bp Consulting, Inc
 2008-06 PHASE4
NCT00579969 TERMINATED
Glaucoma
University of Nebraska
 2003-12 PHASE2
NCT00650338 COMPLETED
Open-Angle Glaucoma; Ocular Hypertension
Santen Inc.
 2008-03 PHASE2
NCT00541242 COMPLETED
Ocular Hypertension; Glaucoma
Allergan
 2007-12 PHASE4
NCT00527592 COMPLETED
Open-Angle Glaucoma; Ocular Hypertension
Alcon Research
 2007-05 PHASE4
NCT00539526 COMPLETED
Open Angle Glaucoma; Ocular Hypertension
Allergan
 2007-09 PHASE4
NCT00620256 COMPLETED
Open-Angle Glaucoma; Ocular Hypertension
Alcon Research
 2007-11 PHASE2
NCT00596791 COMPLETED
Ocular Hypertension; Open-Angle Glaucoma
Santen Oy
 2008-01 PHASE3
NCT00595101 COMPLETED
Primary Open Angle Glaucoma; Ocular Hypertension
Bausch & Lomb Incorporated
 2007-12 PHASE2
NCT00402493 COMPLETED
Glaucoma; Ocular Hypertension
Philadelphia Eye Associates
 2006-12
NCT00441883 COMPLETED
Primary Open Angle Glaucoma; Ocular Hypertension; Pigmentary Glaucoma; Pseudoexfoliative Glaucoma
Bausch & Lomb Incorporated
 2007-03 PHASE2
NCT00906594 COMPLETED
Glaucoma
University of Sao Paulo
 2007-09 PHASE4
NCT00397241 COMPLETED
Open-angle Glaucoma
Aristotle University Of Thessaloniki
 2006-09 PHASE4
NCT00440011 COMPLETED
Glaucoma; Ocular Hypertension
Allergan
 2006-08 PHASE4
NCT00230763 COMPLETED
Glaucoma, Primary Open Angle (POAG); Ocular Hypertension
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
 2005-09 PHASE3
NCT00804115 UNKNOWN
Exfoliation Syndrome; Glaucoma; Ocular Hypertension
The New York Eye & Ear Infirmary
 2000-08
NCT00330577 COMPLETED
Primary Open Angle Glaucoma; Ocular Hypertension
Aristotle University Of Thessaloniki
 2006-04 PHASE4
NCT00440141 COMPLETED
Glaucoma; Ocular Hypertension
Allergan
 2006-07 PHASE4
NCT00187577 COMPLETED
Alopecia Areata
University of California, San Francisco
 2005-06
NCT00287521 COMPLETED
Open-angle Glaucoma; Ocular Hypertension
Alcon Research
 2005-11 PHASE2
NCT00293800 COMPLETED
Open-Angle Glaucoma; Ocular Hypertension
Alcon Research
 2004-07 PHASE3
NCT00293787 COMPLETED
Open-angle Glaucoma; Ocular Hypertension
Alcon Research
 2004-06 PHASE3
NCT00308945 COMPLETED
Open-Angle Glaucoma
University Hospital, Basel, Switzerland
 2003-11 PHASE4
NCT02154217 COMPLETED
Glaucoma
University of Milan
 PHASE3
NCT00311389 COMPLETED
Glaucoma, Open-angle; Ocular Hypertension
Alcon Research
 2003-01 PHASE3
NCT00051155 COMPLETED
Glaucoma, Open-Angle; Ocular Hypertension
Alcon Research
 2001-01 PHASE3
NCT00051142 COMPLETED
Glaucoma, Open-Angle; Ocular Hypertension
Alcon Research
 2001-02 PHASE3
NCT01655758 COMPLETED
Ocular Hypertension
University of Parma
 2002-01 PHASE4
NCT00069706 COMPLETED
Open-angle Glaucoma; Ocular Hypertension
Alcon Research
 2003-07 PHASE2
NCT00051181 COMPLETED
Glaucoma, Angle-Closure; Ocular Hypertension
Alcon Research
 2000-01 PHASE3
NCT01379144 COMPLETED
Primary Open Angle Glaucoma; Ocular Hypertension
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
 2003-01 PHASE2
NCT00847483 COMPLETED
Glaucoma; Ocular Hypertension
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
 2002-01 PHASE4
NCT00800267 COMPLETED
Ocular Hypertension; Glaucoma
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
 1997-07 PHASE3
NCT00856622 COMPLETED
Ocular Hypertension; Glaucoma; Open-angle Glaucoma
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
 1997-08 PHASE3
NCT00751127 COMPLETED
Glaucoma; Open Angle Glaucoma; Ocular Hypertension
Pfizer
 1993-01 PHASE3
NCT00304785 COMPLETED
Open-Angle Glaucoma; Ocular Hypertension
Pharmaceutical Research Network
 2005-05 PHASE4
NCT00219596 COMPLETED
Glaucoma, Open Angle; Ocular Hypertension
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
 2005-06 PHASE3
NCT00273481 COMPLETED
Open-Angle Glaucoma; Ocular Hypertension
Pharmaceutical Research Network
 2005-09 PHASE4
NCT00442312 UNKNOWN
Glaucoma
Genovate Biotechnology Co., Ltd.,
 2006-05 PHASE4
NCT00140049 COMPLETED
Glaucoma, Open Angle; Ocular Hypertension
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
 2005-07 PHASE4
NCT00567788 UNKNOWN
Glaucoma, Angle-Closure
Singapore National Eye Centre
 2006-07
NCT00515424 COMPLETED
Glaucoma; Ocular Hypertension
Novartis
 2007-07 PHASE1
NCT00143208 COMPLETED
Glaucoma; Ocular Hypertension
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
 2003-05 PHASE4
NCT00347841 COMPLETED
Glaucoma
Innovative Medical
 PHASE4
NCT00140062 COMPLETED
Ocular Hypertension; Glaucoma, Open-Angle
Pfizer
 2002-02 PHASE4
NCT00348400 COMPLETED
Glaucoma
Innovative Medical
 PHASE4
NCT00273429 COMPLETED
Open-Angle Glaucoma; Ocular Hypertension
Pharmaceutical Research Network
 2005-04 PHASE4
NCT00647101 COMPLETED
Glaucoma, Open-Angle; Ocular Hypertension
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
 2003-12 PHASE4
NCT00329095 COMPLETED
Glaucoma; Ocular Hypertension
Robin, Alan L., M.D.
 2005-12 PHASE4

(data from https://clinicaltrials.gov, updated on 2026-07-13)

Check the Latanoprost product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Latanoprost is a prostaglandin F2alpha analogue that selectively binds to and activates the prostanoid FP receptor. This receptor activation enhances uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure for the therapeutic management of open-angle glaucoma and ocular hypertension.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.